Riluzole
- Generic Name
- Riluzole
- Brand Names
- Exservan, Rilutek, Tiglutik, Riluzole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H5F3N2OS
- CAS Number
- 1744-22-5
- Unique Ingredient Identifier
- 7LJ087RS6F
- Background
A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis. Riluzole is marketed as Rilutek by Sanofi.
- Indication
For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)
- Associated Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Associated Therapies
- -
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Interventions
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 84
- Registration Number
- NCT00818389
- Locations
- 🇺🇸
Cedars-Sinai ALS Center, Neurology Specialty Clinic, 8730 Alden Drive, Thalians, E 245, Los Angeles, California, United States
🇺🇸Ohio State University, Neuromuscular Division, 1654 Uphan Drive, 417 Means Hall, Columbus, Ohio, United States
🇨🇦University of Saskatchewan, Saskatoon City Hospital, 701 Queen Street, Room 7717 - 7th Floor, Saskatoon, Saskatchewan, Canada
Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder
- Conditions
- Interventions
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Target Recruit Count
- 6
- Registration Number
- NCT00805493
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA)
- First Posted Date
- 2008-10-17
- Last Posted Date
- 2013-02-15
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 141
- Registration Number
- NCT00774423
- Locations
- 🇫🇷
Hopital Raymond Poincare, Garches, France
Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery
- Conditions
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2009-12-11
- Target Recruit Count
- 15
- Registration Number
- NCT00667901
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Riluzole in the Treatment of Bipolar Depression
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT00544544
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
CARE Canadian ALS Riluzole Evaluation
- Conditions
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2007-10-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 414
- Registration Number
- NCT00542412
- Locations
- 🇨🇦
Sanofi-Aventis, Laval, Quebec, Canada
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Yale University
- Target Recruit Count
- 40
- Registration Number
- NCT00523718
- Locations
- 🇺🇸
Yale OCD Research Clinic, New Haven, Connecticut, United States
Neuroprotection With Riluzole Patients With Early Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 43
- Registration Number
- NCT00501943
- Locations
- 🇺🇸
UCSF MS Center , 675 Nelson Rising Lane, Suite 221, San Francisco, California, United States
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
- Conditions
- Interventions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT00419003
- Locations
- 🇺🇸
Mount Sinai School of Medicine, New York, New York, United States
A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 94
- Registration Number
- NCT00376220
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.